Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids
Frontiers in Drug Delivery · 19.10.2023 · 3
DOI: 10.3389/fddev.2023.1270584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Drug Delivery, online erschienen am 19.10.2023. Verfasst von Hiroaki Todo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Sakado, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-lamellar liquid crystal (NLLC) structures have gained increasing attention for the controlled release of entrapped drugs. In the present study, an in situ NLLC structure-forming depot formulation through contact with water was developed using a ternary mixture system of soya phosphatidyl choline (SPC), 1, 2-dioleoyl- sn -glycero-3-phosphoglycerol sodium salt (DOPG), and sorbitan trioleate (Span 85), and the long-term release of an entrapped model drug, leuprolide acetate (LA), was investigated using evaluation of in vitro release and in vivo blood concentration–time profiles. Polarized images and small angle X-ray scattering analysis were used to confirm the presence of NLLC structures by contacting the prepared formulation with water. In addition, LA release and blood concentration–time profiles were investigated using in vitro and in vivo experiments, respectively. In situ NLLC constructed formulations by contacting water were achieved using a ternary mixture of SPC, DOPG, and Span 85. In particular, negative curvature was increased with an increase in the amount of Span 85 in the formulation, and an Fd3m structure was obtained with a sustained release of LA. A maintained blood concentration of LA over 21 days was confirmed by subcutaneous ( s.c. ) administration of the formulation. No retained administered formulation at the injection site was confirmed 28 days after administration without any signs of irritation, inflammation, or other apparent toxicity confirmed by visual observation. This result may be helpful for the development of a lipid-based formulation of peptides and proteins with sustained drug release.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, Josai University, Sakado, Japan.
- Farnex Incorporated, Yokohama Joint Research Center, Yokohama, Japan.
- Faculty of Pharmaceutical Sciences, Josai International University, Togane, Japan.
Zitieren
APA
Todo, H., Niki, R., Okada, A., Narita, I., Inamura, K., Ito, A., Itakura, S., Hijikuro, I., & Sugibayashi, K. (2023). Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids. Frontiers in Drug Delivery, 3. https://doi.org/10.3389/fddev.2023.1270584
Vancouver
Todo H, Niki R, Okada A, Narita I, Inamura K, Ito A, et al. Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids. Frontiers in Drug Delivery. 2023;3. doi:10.3389/fddev.2023.1270584
BibTeX
@article{Todo2023,
author = {Todo, Hiroaki and Niki, Rina and Okada, Akie and Narita, Ibuki and Inamura, Kazuya and Ito, Ayu and Itakura, Shoko and Hijikuro, Ichiro and Sugibayashi, Kenji},
title = {Development of a depot formulation with an in situ non-lamellar liquid crystal-forming system with phospholipids},
journal = {Frontiers in Drug Delivery},
year = {2023},
volume = {3},
doi = {10.3389/fddev.2023.1270584}
}
EUVIMED